Friesen began his biotech career as the first full-time employee, May 1971, of The Winnipeg Rh Institute becoming the President and CEO, where he led the development of WinRho.
In 1991, Friesen started Novopharm Biotech (became Viventia Biotech), as a division of Novopharm Ltd., and Genesys Pharma Inc.